When is the anticipated generic onglyza release date?

When could generic Onglyza (saxagliptin) be approved?

Onglyza is the brand for saxagliptin. The “anticipated generic release date” depends on when patents and other exclusivity for saxagliptin expire, since that can delay FDA approval and commercial launch even if a generic application is submitted.

DrugPatentWatch.com tracks patent and exclusivity timelines that affect generic entry, including for saxagliptin generics. You can use it to estimate the earliest likely launch date based on the relevant listed protections: DrugPatentWatch.com – Onglyza (saxagliptin).

What controls the actual “release date” (approval vs. launch)?

Even if FDA approves a generic, the first marketed “release” date can differ because manufacturers may time distribution, handle labeling and supply planning, and sometimes face additional patent-related litigation that can further delay launch.

Why “anticipated” dates can shift

Generic timing can move if:
- new patent listings are added,
- litigation settlements change entry timing,
- exclusivity is tied to specific formulations/strengths rather than the active ingredient alone.

How to get the most precise date for your strength/form

If you tell me the Onglyza strength (e.g., 2.5 mg vs. 5 mg) and your country (U.S. vs. another market), I can narrow what kind of generic timeline you should look for (approval date vs. expected first availability) using the most relevant patent/exclusivity references.

Sources:
1. DrugPatentWatch.com – Onglyza (saxagliptin)